Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6177925 | 0.86 | CASP1 (0.41) | ADRB2ADRB1ADRB3GAACASP1 | |
| Hydrochloric Acid SCHEMBL27845537 | 0.83 | ADRB2 (0.47) | ADRB2ADRB1ADRB3GAACASP1 | |
| SCHEMBL1186570 | 0.83 | GAA (0.67) | GAACASP1TSHRALDH1A1NR1H2 | |
| SCHEMBL12301378 | 0.82 | KMT2A (0.44) | MAPT | |
| SCHEMBL436207 | 0.81 | ALDH1A1 (0.51) | ADRB2ADRB1ADRB3GAACASP1 | |
| SCHEMBL355847 | 0.81 | GAA (0.44) | ADRB2ADRB1ADRB3GAAALDH1A1 | |
| SCHEMBL355647 | 0.81 | NR1H4 (0.56) | GAACASP1TSHRALDH1A1NR1H2 | |
| SCHEMBL2011456 | 0.81 | CA1 (0.42) | ADRB2ADRB1ADRB3GAACASP1 | |
| SCHEMBL14785200 | 0.81 | CA1 (0.42) | ADRB2ADRB1ADRB3GAACASP1 | |
| SCHEMBL25143250 | 0.81 | EGFR (0.48) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587427-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCERS | BenevolentAI Cambridge Limited (GB) | 2025-07-23 | — | — | EP | disclosed |
| CN-120152958-A | Compounds and their use in the treatment of neurodegenerative disorders and cancer | 博善人工智能剑桥有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2024057001-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCERS | Benevolentai Cambridge Limited (GB) | 2024-03-21 | — | — | WO | disclosed |
| EP-3722291-B1 | INDOLINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES | RESPIVERT LTD (GB) | 2023-07-19 | — | — | EP | disclosed |
| EP-3722291-B1 | INDOLINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES | RESPIVERT LTD (GB) | 2023-07-19 | — | — | EP | disclosed |
| US-11046672-B2 | Indolinones compounds and their use in the treatment of fibrotic diseases | RESPIVERT LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| US-11046672-B2 | Indolinones compounds and their use in the treatment of fibrotic diseases | RESPIVERT LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| CN-109302846-B | Indolinone compounds and their use in the treatment of fibrotic diseases | 莱斯彼维特有限公司 | 2021-05-11 | — | — | CN | disclosed |
| EP-3722291-A1 | INDOLINONES COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES | Respivert Limited (GB) | 2020-10-14 | — | — | EP | disclosed |
| EP-3722291-A1 | INDOLINONES COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES | Respivert Limited (GB) | 2020-10-14 | — | — | EP | disclosed |
| EP-3394048-B1 | INDOLINONES COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES | RESPIVERT LTD (GB) | 2020-03-11 | — | — | EP | disclosed |
| US-20190337929-A1 | INDOLINONES COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES | RESPIVERT LIMITED (GB) | 2019-11-07 | — | — | US | disclosed |
| US-20190337929-A1 | INDOLINONES COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES | RESPIVERT LIMITED (GB) | 2019-11-07 | — | — | US | disclosed |
| CN-109302846-A | Indolinone compounds and their use in the treatment of fibrotic diseases | 莱斯彼维特有限公司 | 2019-02-01 | — | — | CN | disclosed |
| WO-2017109513-A1 | INDOLINONES COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES | RESPIVERT LIMITED (GB) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017063754-A1 | CONFORMATIONALLY CONSTRAINED MACROCYCLIC COMPOUNDS AS PIN1 MODULATORS | POLYPHOR AG (CH) | 2017-04-20 | — | — | WO | disclosed |
| US-7714000-B2 | Substituted pyrrolidinones and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | PYCR1, S100A9, REV1 | ADRB2 571/4885ADRB1 359/4885ADRB3 743/4885 |
| US-11046672-B2 | Indolinones compounds and their use in the treatment of fibrotic diseases | IDO1, INMT, IDO2 | ADRB2 38/4885ADRB1 20/4885ADRB3 21/4885 |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | SERPINC1, TFPI, F2 | ADRB2 2649/4885ADRB1 2546/4885ADRB3 3315/4885 |
| US-20190337929-A1 | INDOLINONES COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES | IDO1, INMT, IDO2 | ADRB2 38/4885ADRB1 20/4885ADRB3 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.